1. Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.
Eye (Lond) 2015;29:65-79.
2. Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy.
Am J Ophthalmol 1994;117:222-30.
3. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy.
Am J Ophthalmol 1997;123:103-7.
4. Lee JY, Park KA, Oh SY. Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study.
Br J Ophthalmol 2018;102:936-41.
5. Xu L, Wang Y, Jonas JB. Incidence of nonarteritic anterior ischemic optic neuropathy in adult Chinese: the Beijing Eye Study.
Eur J Ophthalmol 2007;17:459-60.
7. Huang HM, Wu PC, Kuo HK, et al. Natural history and visual outcome of nonarteritic anterior ischemic optic neuropathy in Southern Taiwan: a pilot study.
Int Ophthalmol 2020;40:2667-76.
8. Dickersin K, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy.
Cochrane Database Syst Rev 2015;2015:CD001538.
9. Ischemic Optic Neuropathy Decompression Trial Research Group. Ischemic optic neuropathy decompression trial: twenty-four-month update.
Arch Ophthalmol 2000;118:793-8.
10. Lantos K, Domotor ZR, Farkas N, et al. Efficacy of treatments in nonarteritic ischemic optic neuropathy: a systematic review and meta-analysis.
Int J Environ Res Public Health 2022;19:2718.
11. Levin LA. Retinal ganglion cells and neuroprotection for glaucoma.
Surv Ophthalmol 2003;48:Suppl 1. S21-4.
13. Hayreh SS. Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy.
Br J Ophthalmol 2020;104:153-6.
14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ 2021;372:n71.
16. Slater BJ, Vilson FL, Guo Y, et al. Optic nerve inflammation and demyelination in a rodent model of nonarteritic anterior ischemic optic neuropathy.
Invest Ophthalmol Vis Sci 2013;54:7952-61.
17. Chang CH, Huang TL, Huang SP, Tsai RK. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in a rat model of anterior ischemic optic neuropathy (rAION).
Exp Eye Res 2014;118:109-16.
18. Wen YT, Huang TL, Huang SP, et al. Early applications of granulocyte colony-stimulating factor (G-CSF) can stabilize the blood-optic-nerve barrier and ameliorate inflammation in a rat model of anterior ischemic optic neuropathy (rAION).
Dis Model Mech 2016;9:1193-202.
20. Georgiou T, Wen YT, Chang CH, et al. Neuroprotective effects of omega-3 polyunsaturated fatty acids in a rat model of anterior ischemic optic neuropathy.
Invest Ophthalmol Vis Sci 2017;58:1603-11.
21. Huang TL, Wen YT, Ho YC, et al. Algae oil treatment protects Retinal Ganglion Cells (RGCs) via ERK signaling pathway in experimental optic nerve ischemia.
Mar Drugs 2020;18:83.
22. Wen YT, Huang CW, Liu CP, et al. Inhibition of retinal ganglion cell loss by a novel ROCK inhibitor (E212) in ischemic optic nerve injury via antioxidative and anti-inflammatory actions.
Invest Ophthalmol Vis Sci 2021;62:21.
24. Le MA, Nguyen Ngo Y, Wen T, et al. Therapeutic effects of puerarin against anterior ischemic optic neuropathy through antiapoptotic and anti-inflammatory actions.
Invest Ophthalmol Vis Sci 2019;60:3481-91.
25. Guo Y, Mehrabian Z, Johnson MA, et al. Topical trabodenoson is neuroprotective in a rodent model of anterior ischemic optic neuropathy (rNAION).
Transl Vis Sci Technol 2019;8:47.
26. Wen YT, Ho YC, Lee YC, et al. The benefits and hazards of intravitreal Mesenchymal Stem Cell (MSC) based-therapies in the experimental ischemic optic neuropathy.
Int J Mol Sci 2021;22:2117.
27. Lin WN, Kapupara K, Wen YT, et al. Haematococcus pluvialis-derived astaxanthin is a potential neuroprotective agent against optic nerve ischemia.
Mar Drugs 2020;18:85.
28. Mehrabian Z, Guo Y, Weinreich D, Bernstein SL. Oligodendrocyte death, neuroinflammation, and the effects of minocycline in a rodent model of nonarteritic anterior ischemic optic neuropathy (rNAION).
Mol Vis 2017;23:963-76.
29. Goldenberg-Cohen N, Dadon-Bar-El S, Hasanreisoglu M, et al. Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy.
Clin Exp Ophthalmol 2009;37:718-29.
30. Allen RS, Olsen TW, Sayeed I, et al. Progesterone treatment in two rat models of ocular ischemia.
Invest Ophthalmol Vis Sci 2015;56:2880-91.
31. Chou YY, Chien JY, Ciou JW, Huang SP. The protective effects of n-butylidenephthalide on retinal ganglion cells during ischemic injury.
Int J Mol Sci 2022;23:2095.
32. Li L, Su Y, Liu J, Chen C. Efficacy of Vincamine treatment in a rat model of anterior ischemic optic neuropathy.
Eur J Ophthalmol 2021;31:3442-9.
33. Johnson MA, Mehrabian Z, Guo Y, et al. Anti-NOGO antibody neuroprotection in a rat model of NAION.
Transl Vis Sci Technol 2021;10:12.
34. Touitou V, Johnson MA, Guo Y, et al. Sustained neuroprotection from a single intravitreal injection of PGJ2 in a rodent model of anterior ischemic optic neuropathy.
Invest Ophthalmol Vis Sci 2013;54:7402-9.
35. Bernstein SL, Mehrabyan Z, Guo Y, Moianie N. Estrogen is not neuroprotective in a rodent model of optic nerve stroke.
Mol Vis 2007;13:1920-5.
36. Avraham-Lubin BC, Dratviman-Storobinsky O, El SD, et al. Neuroprotective effect of hyperbaric oxygen therapy on anterior ischemic optic neuropathy.
Front Neurol 2011;2:23.
37. Lyttle DP, Johnson LN, Margolin EA, Madsen RW. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy.
Graefes Arch Clin Exp Ophthalmol 2016;254:757-64.
38. Nikkhah H, Golalipour M, Doozandeh A, et al. The effect of systemic erythropoietin and oral prednisolone on recent-onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial.
Graefes Arch Clin Exp Ophthalmol 2020;258:2291-7.
39. Parisi V, Barbano L, Di Renzo A, et al. Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: a randomized pilot study.
PLoS One 2019;14:e0220435.
41. McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.
Res Synth Methods 2021;12:55-61.
42. Sterne JA, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials.
BMJ 2019;366:l4898.
44. Barkana Y, Belkin M. Neuroprotection in ophthalmology: a review.
Brain Res Bull 2004;62:447-53.
45. Park CH, Kim YS, Noh HS, et al. Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina.
Exp Eye Res 2005;81:350-8.
46. Rejdak R, Toczolowski J, Solski J, et al. Citicoline treatment increases retinal dopamine content in rabbits.
Ophthalmic Res 2002;34:146-9.
47. Peeler C, Cestari DM. Non-arteritic anterior ischemic optic neuropathy (NAION): a review and update on animal models.
Semin Ophthalmol 2016;31:99-106.
48. Huang TL, Wen YT, Chang CH, et al. Efficacy of intravitreal injections of triamcinolone acetonide in a rodent model of nonarteritic anterior ischemic optic neuropathy.
Invest Ophthalmol Vis Sci 2016;57:1878-84.